ENANTA PHARMACEUTICALS, INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ENANTA PHARMACEUTICALS, INC (ENTA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $8.94 per share for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-12-31 was $8.93, a 0.67% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-12-31 was $8.99.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-12-31 was $20.25, a 51.91% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $8.97, a 0.22% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $8.99, a 49.58% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $17.83, a 56.69% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $41.17, a 47.09% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $8.94 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $8.93 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $8.93 10-Q · filed 2026-02-11 | ||||
| 2025-09-30 | $8.97 10-K · filed 2025-11-19 | ||||
| 2025-06-30 | $8.99 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | $8.99 10-Q · filed 2025-05-14 | ||||
| 2024-12-31 | $8.99 10-Q · filed 2025-02-12 | ||||
| 2024-09-30 | $8.99 10-K · filed 2024-11-27 | ||||
| 2024-06-30 | $8.99 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | $8.99 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $0.00 10-Q · filed 2024-02-08 | ||||
| 2023-09-30 | $17.83 10-K · filed 2023-11-22 | ||||
| 2023-03-31 | $17.83 10-Q · filed 2023-08-08 | $17.14 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $20.25 10-Q · filed 2023-02-08 | ||||
| 2022-09-30 | $41.17 10-K · filed 2022-11-23 | ||||
| 2022-06-30 | $41.05 10-Q · filed 2022-08-08 | ||||
| 2022-03-31 | $41.26 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $42.11 10-Q · filed 2022-02-10 | ||||
| 2021-09-30 | $27.99 10-K · filed 2021-11-24 | ||||
| 2021-06-30 | $26.08 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $26.27 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | $25.25 10-Q · filed 2021-02-09 | ||||
| 2020-09-30 | $32.05 10-K · filed 2020-11-25 | ||||
| 2020-06-30 | $32.04 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $29.68 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $30.16 10-Q · filed 2020-02-10 | ||||
| 2019-09-30 | $29.68 10-K · filed 2019-11-27 | ||||
| 2019-06-30 | $29.33 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $28.59 10-Q · filed 2019-05-10 | ||||
| 2018-12-31 | $28.76 10-Q · filed 2019-02-08 | ||||
| 2018-09-30 | $27.23 10-K · filed 2018-11-29 | ||||
| 2018-06-30 | $26.75 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $23.39 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $14.80 10-Q · filed 2018-02-09 | ||||
| 2017-09-30 | $14.95 10-K · filed 2017-12-11 | ||||
| 2017-06-30 | $6.36 10-Q · filed 2017-08-09 | ||||
| 2017-03-31 | $9.82 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | $11.27 10-Q · filed 2017-02-09 | ||||
| 2016-09-30 | $3.22 10-K · filed 2016-12-09 | ||||
| 2016-06-30 | $3.21 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $2.76 10-Q · filed 2016-05-10 | ||||
| 2015-12-31 | $2.07 10-Q · filed 2016-02-09 | ||||
| 2015-09-30 | $5.94 10-K · filed 2015-12-11 | ||||
| 2015-06-30 | $4.88 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $3.54 10-Q · filed 2015-05-08 | ||||
| 2014-12-31 | $5.10 10-Q · filed 2015-02-06 | ||||
| 2014-09-30 | $1.61 10-K · filed 2014-12-11 | ||||
| 2014-06-30 | $1.56 10-Q · filed 2014-08-12 | ||||
| 2014-03-31 | $1.18 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $2.41 10-Q · filed 2014-02-13 | ||||
| 2013-09-30 | $1.04 10-K · filed 2013-12-18 | ||||
| 2013-06-30 | $1.01 10-Q · filed 2013-08-12 | ||||
| 2013-03-31 | $0.97 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |